Plain-English translation of NCT07655622 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
China
Safety & dosing / Early efficacy
Sponsor
Second Affiliated Hospital of Nanchang University
Collaborators
Beijing Pearl Biotechnology Limited Liability Company
Enrollment target
~45 participants
Started
July 2026
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing Cai, MD, PhD
Second Affiliated Hospital of Nanchang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.